CN113677678A - 用于治疗炎性障碍的新化合物及其药物组合物 - Google Patents

用于治疗炎性障碍的新化合物及其药物组合物 Download PDF

Info

Publication number
CN113677678A
CN113677678A CN202080026038.XA CN202080026038A CN113677678A CN 113677678 A CN113677678 A CN 113677678A CN 202080026038 A CN202080026038 A CN 202080026038A CN 113677678 A CN113677678 A CN 113677678A
Authority
CN
China
Prior art keywords
independently selected
substituted
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080026038.XA
Other languages
English (en)
Chinese (zh)
Inventor
O·马莫利蒂
R·C·X·布里斯
G·J·R·纽瑟姆
M·G·巴贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of CN113677678A publication Critical patent/CN113677678A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080026038.XA 2019-03-29 2020-03-24 用于治疗炎性障碍的新化合物及其药物组合物 Pending CN113677678A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1904375.1 2019-03-29
GBGB1904375.1A GB201904375D0 (en) 2019-03-29 2019-03-29 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
PCT/EP2020/058061 WO2020200898A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
CN113677678A true CN113677678A (zh) 2021-11-19

Family

ID=66442789

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080026038.XA Pending CN113677678A (zh) 2019-03-29 2020-03-24 用于治疗炎性障碍的新化合物及其药物组合物

Country Status (14)

Country Link
US (1) US20220296573A1 (https=)
EP (1) EP3947374A1 (https=)
JP (1) JP2022526553A (https=)
KR (1) KR20210143905A (https=)
CN (1) CN113677678A (https=)
AU (1) AU2020252900A1 (https=)
BR (1) BR112021019099A2 (https=)
CA (1) CA3134732A1 (https=)
GB (1) GB201904375D0 (https=)
IL (1) IL286688A (https=)
MX (1) MX2021011574A (https=)
PH (1) PH12021552377A1 (https=)
SG (1) SG11202110643YA (https=)
WO (1) WO2020200898A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54755A (fr) * 2019-01-18 2021-11-24 Biogen Ma Inc Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
KR20230059584A (ko) 2021-10-26 2023-05-03 주식회사 엘지에너지솔루션 전극 조립체의 제조방법
WO2023098857A1 (zh) * 2021-12-03 2023-06-08 武汉人福创新药物研发中心有限公司 Irak4抑制剂及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1835950A (zh) * 2003-08-15 2006-09-20 万有制药株式会社 咪唑并吡啶衍生物
CN1950372A (zh) * 2004-05-10 2007-04-18 万有制药株式会社 咪唑并吡啶化合物
WO2012129258A1 (en) * 2011-03-22 2012-09-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
CN105143221A (zh) * 2013-03-14 2015-12-09 加拉帕戈斯股份有限公司 用于治疗炎性障碍的化合物及其药物组合物
CN106458982A (zh) * 2014-01-10 2017-02-22 奥列基因发现技术有限公司 作为irak4抑制剂的吲唑化合物
CN108473498A (zh) * 2015-12-22 2018-08-31 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018060174A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln
WO2018060072A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
MA54755A (fr) * 2019-01-18 2021-11-24 Biogen Ma Inc Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1835950A (zh) * 2003-08-15 2006-09-20 万有制药株式会社 咪唑并吡啶衍生物
CN1950372A (zh) * 2004-05-10 2007-04-18 万有制药株式会社 咪唑并吡啶化合物
WO2012129258A1 (en) * 2011-03-22 2012-09-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
US20140194404A1 (en) * 2011-03-22 2014-07-10 William T. McElroy Amidopyrazole inhibitors of interleukin receptor-associated kinases
CN105143221A (zh) * 2013-03-14 2015-12-09 加拉帕戈斯股份有限公司 用于治疗炎性障碍的化合物及其药物组合物
CN106458982A (zh) * 2014-01-10 2017-02-22 奥列基因发现技术有限公司 作为irak4抑制剂的吲唑化合物
CN108473498A (zh) * 2015-12-22 2018-08-31 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物

Also Published As

Publication number Publication date
AU2020252900A1 (en) 2021-11-25
SG11202110643YA (en) 2021-10-28
PH12021552377A1 (en) 2022-10-03
US20220296573A1 (en) 2022-09-22
KR20210143905A (ko) 2021-11-29
MX2021011574A (es) 2021-10-13
JP2022526553A (ja) 2022-05-25
WO2020200898A1 (en) 2020-10-08
GB201904375D0 (en) 2019-05-15
EP3947374A1 (en) 2022-02-09
BR112021019099A2 (pt) 2021-11-30
CA3134732A1 (en) 2020-10-08
IL286688A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
CN113924146B (zh) 用于治疗疾病的新化合物及其药物组合物
CN111433200B (zh) 用于治疗疾病的化合物及其药物组合物
CN113677678A (zh) 用于治疗炎性障碍的新化合物及其药物组合物
EP3947378B1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EA024743B1 (ru) Соединение, предназначенное для лечения дегенеративных и воспалительных состояний
JP6472454B2 (ja) 炎症性疾患治療のためのベンゾイミダゾール誘導体及びその医薬組成物
CN113677679A (zh) 用于治疗炎性障碍的新化合物及其药物组合物
EP3365341B1 (en) 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
KR20190117672A (ko) Ｉｒａｋ 및 ｊａｋ 억제제를 포함하는 항염 조성물
KR102511209B1 (ko) 벤즈이미다졸 유도체 및 염증 질환의 치료를 위한 그의 약학 조성물
RU2782375C2 (ru) Новые соединения и их фармацевтические композиции для лечения заболеваний
WO2025068090A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211119